Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease

go back to reference Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 DIAGNOSIS and Staging Working Group report. Biol Blood Marrow Transpl 21(3):389–401. doi:10.1016/j.bbmt.2014.12.001 CrossRef Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 DIAGNOSIS and Staging Working Group report. Biol Blood Marrow Transpl 21(3):389–401. doi:10.​1016/​j.​bbmt.​2014.​12.​001 CrossRef

go back to reference Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringden OT, Savani BN, Socie G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Perez-Simon JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhauser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ, Graft-vs-Host Disease Working Committee of the C (2015) Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transpl 21(2):266–274. doi:10.1016/j.bbmt.2014.10.021 CrossRef Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringden OT, Savani BN, Socie G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Perez-Simon JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhauser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ, Graft-vs-Host Disease Working Committee of the C (2015) Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transpl 21(2):266–274. doi:10.​1016/​j.​bbmt.​2014.​10.​021 CrossRef

go back to reference Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S, Mattsson J, Svahn BM, Winiarski J, Ljungman P, Aschan J (1998) Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transpl 22(8):755–761. doi:10.1038/sj.bmt.1701423 CrossRef Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S, Mattsson J, Svahn BM, Winiarski J, Ljungman P, Aschan J (1998) Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transpl 22(8):755–761. doi:10.​1038/​sj.​bmt.​1701423 CrossRef

go back to reference Ochs LA, Miller WJ, Filipovich AH, Haake RJ, McGlave PB, Blazar BR, Ramsay NK, Kersey JH, Weisdorf DJ (1994) Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transpl 13(4):455–460 Ochs LA, Miller WJ, Filipovich AH, Haake RJ, McGlave PB, Blazar BR, Ramsay NK, Kersey JH, Weisdorf DJ (1994) Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transpl 13(4):455–460

go back to reference Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl 11(12):945–956. doi:10.1016/j.bbmt.2005.09.004 CrossRef Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl 11(12):945–956. doi:10.​1016/​j.​bbmt.​2005.​09.​004 CrossRef

go back to reference Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, Arai S, Arora M, Jagasia M, Cutler C, Weisdorf D, Martin PJ, Pavletic SZ, Vogelsang G, Lee SJ, Flowers ME (2012) Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 120(13):2545–2552. doi:10.1182/blood-2012-04-424135 quiz 2774 CrossRefPubMedPubMedCentral Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, Arai S, Arora M, Jagasia M, Cutler C, Weisdorf D, Martin PJ, Pavletic SZ, Vogelsang G, Lee SJ, Flowers ME (2012) Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 120(13):2545–2552. doi:10.​1182/​blood-2012-04-424135 quiz 2774 CrossRefPubMedPubMedCentral

go back to reference Yanik G, Kitko C (2013) Management of noninfectious lung injury following hematopoietic cell transplantation. Curr Opin Oncol 25(2):187–194. doi:10.1097/CCO.0b013e32835dc8a5 CrossRefPubMed Yanik G, Kitko C (2013) Management of noninfectious lung injury following hematopoietic cell transplantation. Curr Opin Oncol 25(2):187–194. doi:10.​1097/​CCO.​0b013e32835dc8a5​ CrossRefPubMed

go back to reference Williams KM, Chien JW, Gladwin MT, Pavletic SZ (2009) Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 302(3):306–314. doi:10.1001/jama.2009.1018 CrossRefPubMed Williams KM, Chien JW, Gladwin MT, Pavletic SZ (2009) Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 302(3):306–314. doi:10.​1001/​jama.​2009.​1018 CrossRefPubMed

go back to reference Chi AK, Soubani AO, White AC, Miller KB (2013) An update on pulmonary complications of hematopoietic stem cell transplantation. Chest 144(6):1913–1922. doi:10.1378/chest.12-1708 CrossRefPubMed Chi AK, Soubani AO, White AC, Miller KB (2013) An update on pulmonary complications of hematopoietic stem cell transplantation. Chest 144(6):1913–1922. doi:10.​1378/​chest.​12-1708 CrossRefPubMed

go back to reference Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, Dominique S, de Revel T, Juvin K, Maillard N, Reman O, Contentin N, Robin M, Buzyn A, Socie G, Tazi A (2015) Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med 191(11):1242–1249. doi:10.1164/rccm.201410-1818OC CrossRefPubMed Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, Dominique S, de Revel T, Juvin K, Maillard N, Reman O, Contentin N, Robin M, Buzyn A, Socie G, Tazi A (2015) Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med 191(11):1242–1249. doi:10.​1164/​rccm.​201410-1818OC CrossRefPubMed

go back to reference Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff D (2011) Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transpl 46(10):1283–1295. doi:10.1038/bmt.2011.35 CrossRef Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff D (2011) Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transpl 46(10):1283–1295. doi:10.​1038/​bmt.​2011.​35 CrossRef

go back to reference Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee SJ, Moravec CK, Chien JW (2011) Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transpl 46(10):1369–1373. doi:10.1038/bmt.2010.311 CrossRef Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee SJ, Moravec CK, Chien JW (2011) Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transpl 46(10):1369–1373. doi:10.​1038/​bmt.​2010.​311 CrossRef

go back to reference Brownback KR, Simpson SQ, Pitts LR, Polineni D, McGuirk JP, Ganguly S, Aljitawi OS, Lin TL, Singh A, Abhyankar S (2015) Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. J Clin Apheresis. doi:10.1002/jca.21404 PubMed Brownback KR, Simpson SQ, Pitts LR, Polineni D, McGuirk JP, Ganguly S, Aljitawi OS, Lin TL, Singh A, Abhyankar S (2015) Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. J Clin Apheresis. doi:10.​1002/​jca.​21404 PubMed

go back to reference Del Fante C, Galasso T, Bernasconi P, Scudeller L, Ripamonti F, Perotti C, Meloni F (2016) Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. Bone Marrow Transpl 51(5):728–731. doi:10.1038/bmt.2015.324 CrossRef Del Fante C, Galasso T, Bernasconi P, Scudeller L, Ripamonti F, Perotti C, Meloni F (2016) Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. Bone Marrow Transpl 51(5):728–731. doi:10.​1038/​bmt.​2015.​324 CrossRef

go back to reference Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL, Vaughan LA, Kassim A, Schuening F, Jagasia M (2011) Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transpl 46(3):426–429. doi:10.1038/bmt.2010.152 CrossRef Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL, Vaughan LA, Kassim A, Schuening F, Jagasia M (2011) Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transpl 46(3):426–429. doi:10.​1038/​bmt.​2010.​152 CrossRef

go back to reference Alousi AM, Uberti J, Ratanatharathorn V (2010) The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 51(3):376–389. doi:10.3109/10428190903586318 CrossRefPubMed Alousi AM, Uberti J, Ratanatharathorn V (2010) The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 51(3):376–389. doi:10.​3109/​1042819090358631​8 CrossRefPubMed

go back to reference Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, Hochberg EP, Wu CJ, Alyea EP, Cutler C, Ho V, Soiffer RJ, Antin JH, Ritz J (2005) Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105(7):2973–2978. doi:10.1182/blood-2004-09-3660 CrossRefPubMed Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, Hochberg EP, Wu CJ, Alyea EP, Cutler C, Ho V, Soiffer RJ, Antin JH, Ritz J (2005) Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105(7):2973–2978. doi:10.​1182/​blood-2004-09-3660 CrossRefPubMed

go back to reference Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, Viatte S, Soiffer RJ, Antin JH, Ritz J (2004) Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 103(1):353–359. doi:10.1182/blood-2003-03-0984 CrossRefPubMed Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, Viatte S, Soiffer RJ, Antin JH, Ritz J (2004) Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 103(1):353–359. doi:10.​1182/​blood-2003-03-0984 CrossRefPubMed

go back to reference Clavert A, Chevallier P, Guillaume T, Delaunay J, Le Gouill S, Mahe B, Dubruille V, Gastinne T, Blin N, Moreau P, Mohty M (2013) Safety and efficacy of rituximab in steroid-refractory chronic GVHD. Bone Marrow Transpl 48(5):734–736. doi:10.1038/bmt.2012.203 CrossRef Clavert A, Chevallier P, Guillaume T, Delaunay J, Le Gouill S, Mahe B, Dubruille V, Gastinne T, Blin N, Moreau P, Mohty M (2013) Safety and efficacy of rituximab in steroid-refractory chronic GVHD. Bone Marrow Transpl 48(5):734–736. doi:10.​1038/​bmt.​2012.​203 CrossRef

go back to reference Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E (2006) Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108(2):756–762. doi:10.1182/blood-2006-01-0233 CrossRefPubMedPubMedCentral Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E (2006) Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108(2):756–762. doi:10.​1182/​blood-2006-01-0233 CrossRefPubMedPubMedCentral

go back to reference Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH (2010) Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 95(11):1935–1942. doi:10.3324/haematol.2010.026104 CrossRefPubMedPubMedCentral Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH (2010) Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 95(11):1935–1942. doi:10.​3324/​haematol.​2010.​026104 CrossRefPubMedPubMedCentral

go back to reference Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A (2015) Corticosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab. Biol Blood Marrow Transpl. doi:10.1016/j.bbmt.2015.04.023 Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A (2015) Corticosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab. Biol Blood Marrow Transpl. doi:10.​1016/​j.​bbmt.​2015.​04.​023

go back to reference Lorillon G, Robin M, Meignin V, Ribaud P, Lescoeur B, Gossot D, Socie G, Tazi A, Bergeron A (2011) Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation. Eur Respir J 38(2):470–472. doi:10.1183/09031936.00003711 CrossRefPubMed Lorillon G, Robin M, Meignin V, Ribaud P, Lescoeur B, Gossot D, Socie G, Tazi A, Bergeron A (2011) Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation. Eur Respir J 38(2):470–472. doi:10.​1183/​09031936.​00003711 CrossRefPubMed

go back to reference Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A, Blazar BR (2012) Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119(6):1570–1580. doi:10.1182/blood-2011-07-364414 CrossRefPubMedPubMedCentral Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A, Blazar BR (2012) Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119(6):1570–1580. doi:10.​1182/​blood-2011-07-364414 CrossRefPubMedPubMedCentral

go back to reference Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, Sharf A, Deal AM, Armistead P, Coghill J, Gabriel DA, Irons R, Essenmacher A, Shea TC, Richards K, Cutler C, Ritz J, Serody J, Baldwin AS, Sarantopoulos S (2012) B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 120(12):2529–2536. doi:10.1182/blood-2012-06-438911 CrossRefPubMedPubMedCentral Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, Sharf A, Deal AM, Armistead P, Coghill J, Gabriel DA, Irons R, Essenmacher A, Shea TC, Richards K, Cutler C, Ritz J, Serody J, Baldwin AS, Sarantopoulos S (2012) B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 120(12):2529–2536. doi:10.​1182/​blood-2012-06-438911 CrossRefPubMedPubMedCentral

go back to reference Rafiq K, Bergtold A, Clynes R (2002) Immune complex-mediated antigen presentation induces tumor immunity. J Clin Investig 110(1):71–79. doi:10.1172/JCI15640 CrossRefPubMedPubMedCentral Rafiq K, Bergtold A, Clynes R (2002) Immune complex-mediated antigen presentation induces tumor immunity. J Clin Investig 110(1):71–79. doi:10.​1172/​JCI15640 CrossRefPubMedPubMedCentral

go back to reference Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A (2009) Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transpl 15(9):1005–1013. doi:10.1016/j.bbmt.2009.04.003 CrossRef Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A (2009) Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transpl 15(9):1005–1013. doi:10.​1016/​j.​bbmt.​2009.​04.​003 CrossRef

go back to reference Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB (2012) Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 119(25):6145–6154. doi:10.1182/blood-2011-12-395970 CrossRefPubMedPubMedCentral Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB (2012) Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 119(25):6145–6154. doi:10.​1182/​blood-2011-12-395970 CrossRefPubMedPubMedCentral

go back to reference Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, Rosenblatt J, McDonough S, Watanaboonyongcharoen P, Armand P, Koreth J, Glotzbecker B, Alyea E, Blazar BR, Soiffer RJ, Ritz J, Antin JH (2013) Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 122(8):1510–1517. doi:10.1182/blood-2013-04-495895 CrossRefPubMedPubMedCentral Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, Rosenblatt J, McDonough S, Watanaboonyongcharoen P, Armand P, Koreth J, Glotzbecker B, Alyea E, Blazar BR, Soiffer RJ, Ritz J, Antin JH (2013) Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 122(8):1510–1517. doi:10.​1182/​blood-2013-04-495895 CrossRefPubMedPubMedCentral

go back to reference Benden C, Speich R, Hofbauer GF, Irani S, Eich-Wanger C, Russi EW, Weder W, Boehler A (2008) Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 86(11):1625–1627. doi:10.1097/TP.0b013e31818bc024 CrossRefPubMed Benden C, Speich R, Hofbauer GF, Irani S, Eich-Wanger C, Russi EW, Weder W, Boehler A (2008) Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 86(11):1625–1627. doi:10.​1097/​TP.​0b013e31818bc024​ CrossRefPubMed

go back to reference Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, Renoldi G, Parma M, Balduzzi A, Perseghin P, Biondi A (2007) Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4 + CD25 + GITR + Foxp3 + CD62L + functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 84(1):31–39. doi:10.1097/01.tp.0000267785.52567.9c CrossRefPubMed Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, Renoldi G, Parma M, Balduzzi A, Perseghin P, Biondi A (2007) Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4 + CD25 + GITR + Foxp3 + CD62L + functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 84(1):31–39. doi:10.​1097/​01.​tp.​0000267785.​52567.​9c CrossRefPubMed

go back to reference Axelrod L (1976) Glucocorticoid therapy. Medicine 55(1):39–65CrossRefPubMed Axelrod L (1976) Glucocorticoid therapy. Medicine 55(1):39–65CrossRefPubMed